Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

BMC Ophthalmology Pub Date : 2025-03-14 DOI:10.1186/s12886-025-03958-4

Hamid Ahmadi, Steffen Hamann

{"title":"Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.","authors":"Hamid Ahmadi, Steffen Hamann","doi":"10.1186/s12886-025-03958-4","DOIUrl":null,"url":null,"abstract":"Background: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used worldwide for its cardiometabolic benefits. However, it has recently been associated with nonarteritic anterior ischemic optic neuropathy (NAION). This report presents four clinical cases and explores a possible association.Case presentation: Four male patients were diagnosed with NAION during semaglutide treatment, with treatment durations of less than one year in three cases. All presented with significant optic disc edema and intraretinal fluid on optical coherence tomography, along with crowded optic disc and small Bruch's membrane opening diameters (< 1.4 mm in three cases). One patient exhibited optic disc drusen. Visual field defects corresponded with ganglion cell layer atrophy on optical coherence tomography. Systemic risk factors varied; two patients had only obesity.Conclusions: Our observation suggests that individuals with small Bruch's membrane opening diameter may be at risk of developing NAION during semaglutide treatment.","PeriodicalId":9058,"journal":{"name":"BMC Ophthalmology","volume":"25 1","pages":"132"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908077/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12886-025-03958-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used worldwide for its cardiometabolic benefits. However, it has recently been associated with nonarteritic anterior ischemic optic neuropathy (NAION). This report presents four clinical cases and explores a possible association.

Case presentation: Four male patients were diagnosed with NAION during semaglutide treatment, with treatment durations of less than one year in three cases. All presented with significant optic disc edema and intraretinal fluid on optical coherence tomography, along with crowded optic disc and small Bruch's membrane opening diameters (< 1.4 mm in three cases). One patient exhibited optic disc drusen. Visual field defects corresponded with ganglion cell layer atrophy on optical coherence tomography. Systemic risk factors varied; two patients had only obesity.

Conclusions: Our observation suggests that individuals with small Bruch's membrane opening diameter may be at risk of developing NAION during semaglutide treatment.

查看原文本刊更多论文

用西马鲁肽治疗的患者的前缺血性视神经病变：四例可能相关的病例报告。

背景：Semaglutide是一种胰高血糖素样肽-1受体激动剂，因其对心脏代谢的益处而在世界范围内越来越多地使用。然而，它最近与非动脉性前缺血性视神经病变（NAION）有关。本报告提出了四个临床病例，并探讨了可能的关联。病例介绍：4例男性患者在西马鲁肽治疗期间被诊断为NAION，其中3例治疗持续时间不到一年。所有患者在光学相干断层扫描上均表现出明显的视盘水肿和视网膜内积液，同时视盘拥挤，布鲁氏膜开口直径小(结论：我们的观察表明，在西马鲁肽治疗期间，布鲁氏膜开口直径小的患者可能有发生NAION的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Ophthalmology OPHTHALMOLOGY-

CiteScore

3.40

自引率

5.00%

发文量

441

审稿时长

6-12 weeks

期刊介绍： BMC Ophthalmology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of eye disorders, as well as related molecular genetics, pathophysiology, and epidemiology.